GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions

Feladilimab Phase II Combination Study With Keytruda Halted

 
• By John Davis
  
gloomy autumn day
A Disappointing Day For GSK • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas